The kind people at Mary Ann Liebert, Inc. Publishers have accelerated publication of ASSAY and Drug Development Technologies’ summer special issue: we got sufficient good manuscripts to warrant that. And lo!, this allows us to publish discussions of selected drug repurposing patent applications in a very timely manner. Once again, incredible pharmacological creativity from around the world! Here is the teaser for the 22 PCT documents from Q4/16 and Q1/17 that we have selected. Watch out for the full text at the ASSAY website.
Q4/2016
- Desmopressin syergizes with docetaxel in prostate cancer (WO/2016/164482, Sunnybrook Research Institute, Toronto, Ontario, Canada; published October 6, 2016)
- Wrapping up histone modulation in heart failure – news from the “inostat” drug family (WO/2016/164482, The University of North Carolina at Chapel Hill, Chapel Hill, NC; published October 13, 2016)
- Teratogenic agents as cancer stem cell killers (WO/2016/176675, Nant Holdings IP, Culver City, CA, USA; published November 3, 2016)
- The ACE inhibitor perindopril treat male genetic obesity (WO/2016/178591, Gene Predit SA, Cantanhede, Portugal; published November 10, 2016).
- Deptropine and pizotifen are lysosome migration inhibitors (WO/2016/179481, inventor-applicants; published November 10, 2016)
- Carbonic anhydrase inhibitors for clotting disorders (WO/2016/181135, The University of Bristol, Bristol, UK; published November 17, 2016)
- “Setron” anti-nausea drugs for sensorineural hearing loss (WO/2016/184900, Sensorion SA, Montpellier, France; published November 24, 2016)
- An opioid, an NSAID, an antiretroviral drug, and zebrafish: repurposing for Parkinson’s disease (WO/2016/190766, Technophage, S.A. et al., Portugal)
- Biperiden treats Malt1+ cancers (WO/2016/193339, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; published December
8, 2016) - Terazosine as an anti-aging drug (WO/2016/202099, inventor-applicants; published: December 22, 2016)
- Imatinib for dry eye: exploiting a side effect (WO/2016/208961, Knotus Co., Ltd., Guri-si, Gyeonggi-do, Korea; published
December 29, 2016) - Lorcaserin might improve weakness after sepsis (WO/2016/210431, Wright State University, Dayton, Ohio, USA; published December 29, 2016)
Q1/2017
- Zoledronic acid: From erosive bone cancers to fatty liver disease (WO/2017/000902, Nanjing University, Jiangsu, China; published January 5, 2017)
- Dipyramidole inhibits mesangial cell proliferation in renal diseases (WO/2017/007120, Cho Dang Pharm. Co. Ltd., Seoul, Korea; published January 12, 2017)
- Amitryptilin inhibits CNS connexin hemichannels (WO/2017/009472, Theranexus, Lyon, France; published January 19, 2017)
- Fluoxetine and vortioxetine for congenital myopathies (WO/2017/013031, Institut Pasteur, Paris, France et al.; published January 26, 2017)
- Exhuming failed Alzheimer drugs for hematological immune diseases (WO/2017/019496, (Inventor-applicant; published February 2, 2017)
- NMDA receptor blockers reduce blood-brain barrier permeability (WO/2017/021951, B. G. Negev Technologies and Applications, Ltd., Beer Sheva, Israel; published February 9, 2017)
- Glutathione/gamma-glutamyl pathway modulators for persistent Lyme disease (WO/2017/034984, The Johns Hopkins University, Baltimore, MD, USA; published March 2, 2017)
- GW-501516 and LY-518674: discontinued for major metabolic disorders, re-lifed for rare diseases? (WO/2017/044551, Mitobridge, Inc., Cambridge, MA, USA; published March 16, 2017)
- Niclosamide for cancer: an exercise in extracting novelty from prior art (WO/2017/048197, Agency for Science, Technology and Research, Singapore; IFOM, the FIRC Institute of Molecular Oncology Foundation, Milano, Italy; published March 23, 2017)
- Gentamycin’s nonsense suppression potential rests in its B1 component (WO/2017/049386, The University of British Columbia, Vancouver, Canada; published March 30, 2017)